Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
University of New Mexico |
---|---|
Information provided by: | University of New Mexico |
ClinicalTrials.gov Identifier: | NCT00250029 |
1.1 To collect pathological tumor specimens of patients with metastatic colorectal cancer in a prospective fashion for correlative studies of response to an oxaliplatin based chemotherapy regimen.
1.2 To determine a gene expression profile that predicts response to an oxaliplatin based chemotherapy regimen in this cohort of patients.
Condition | Intervention |
---|---|
Colonic Diseases Cancer |
Drug: Oxaliplatin |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment |
Official Title: | Gene Expression Analysis of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin Based Chemotherapy |
Enrollment: | 30 |
Study Start Date: | April 2004 |
Study Completion Date: | March 2006 |
Primary Completion Date: | September 2005 (Final data collection date for primary outcome measure) |
This is a single-arm, non-randomized trial of oxaliplatin and capecitabine. Patients that are placed on other studies that utilize the same chemotherapy regimen can enter this study. Those patients will be treated according to the clinical study on which they have been entered. For patients not on another clinical trial, the treatment outlined below should be followed.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, New Mexico | |
University of New Mexico | |
Albuquerque, New Mexico, United States, 87131 | |
Hematology Oncology Associates | |
Albuquerque, New Mexico, United States, 87102-3661 | |
Lovelace Sandia Health Systems Dept of Hematology | |
Albuquerque, New Mexico, United States, 87108 | |
New Mexico Veterans Administration Health Care System | |
Albuquerque, New Mexico, United States |
Principal Investigator: | Ian Rabinowitz, MD | University of New Mexico |
Responsible Party: | University of New Mexico - CRTC ( Ian Rabinowitz, MD; Principal Investigator ) |
Study ID Numbers: | 0104C |
Study First Received: | November 3, 2005 |
Last Updated: | October 1, 2008 |
ClinicalTrials.gov Identifier: | NCT00250029 History of Changes |
Health Authority: | United States: Institutional Review Board |
Colorectal Cancer Pilot Study Oxaliplatin |
Antimetabolites Dexamethasone Capecitabine Digestive System Neoplasms Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases |
Serotonin Intestinal Neoplasms Oxaliplatin Digestive System Diseases Gastrointestinal Neoplasms Colorectal Neoplasms Dexamethasone acetate |
Antimetabolites Capecitabine Antimetabolites, Antineoplastic Digestive System Neoplasms Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases |
Pharmacologic Actions Intestinal Neoplasms Neoplasms Oxaliplatin Digestive System Diseases Neoplasms by Site Therapeutic Uses Gastrointestinal Neoplasms Colorectal Neoplasms |